|
Canada-0-TileNonCeramicDistributors ไดเรกทอรีที่ บริษัท
|
ข่าว บริษัท :
- Grb2 inhibition: a new potential targeted therapy for myeloid . . .
The antisense strategy was selected to inhibit Grb2 because of its intracellular location with no enzymatic activity Antisense oligonucleotides selectively bind to target mRNAs and silence disease-associated proteins
- GRB2 Inhibitors - SCBT - Santa Cruz Biotechnology
GRB2 inhibitors work by specifically targeting the GRB2 protein, interfering with its interactions with phosphorylated tyrosine residues on receptors or other signaling proteins
- Novel potent heterocyclic Grb2–SH2 domain antagonists as potential anti . . .
Compound DO71_2 consistently emerges as the most potent competitive inhibitor, with the highest affinity for the Grb2-SH2 domain, as evidenced by its superior performance across all experimental and computational approaches
- Targeting GRB2 with Polyphyllin H overcomes PIKFYVE inhibitor . . .
We identified PPH as a novel GRB2 inhibitor that binds specifically to the c-SH3 SH2 interface via a steric bottleneck involving key residues (Phe62, Ile65, Phe182) PPH suppressed the Akt-SREBP1-SCD1 cascade, inhibiting lipogenesis and tumor proliferation even under lipid-rich conditions
- What are GRB2 inhibitors and how do they work? - Patsnap
By inhibiting GRB2, researchers aim to disrupt these abnormal signaling cascades and, consequently, inhibit tumor growth and progression GRB2 inhibitors work by binding to the SH2 domain of the GRB2 protein, preventing it from interacting with phosphorylated tyrosine residues on activated RTKs
- Synthesis and Structural Characterization of a Monocarboxylic Inhibitor . . .
In summary, we designed a new monocarboxylic inhibitor for GRB2 SH2 domain, compound 7 in Fig 1B, and developed a robust synthetic route to synthesize this class of macrocyclic peptides
- NHD2-15, a novel antagonist of Growth Factor Receptor-Bound . . . - PLOS
Utilizing novel synthetic methods, we developed four furo-quinoxaline compounds as GRB2 SH2 domain antagonists with the goal of disrupting this leukemogenic signaling One of the four antagonists, NHD2-15, showed a significant reduction in proliferation of K562 cells, a human BCR-ABL1+leukemic cell line
- GRB2 stabilizes RAD51 at reversed replication forks . . . - Nature
GRB2 alleviates oncogenic replication stress, and in doing so, averts cancer immune destruction by inhibiting cGAS STING and pro-inflammatory cytokine production
- Development of Grb2 SH2 Domain Signaling Antagonists: A Potential New . . .
This review has presented an overview of Grb2 SH2 domain-directed inhibitor development Although several high affinity inhibitors have been reported, including agents that exhibit potent effects in cellular systems, studies in whole animal cancer models have yet to appear
- Synthesis and structural characterization of a monocarboxylic inhibitor . . .
In summary, we designed a new monocarboxylic inhibitor for GRB2 SH2 domain, compound 7 in Fig 1B, and developed a robust synthetic route to synthesize this class of macrocyclic peptides
|
|